Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings
This week: MAPS’ second Phase 3 study of MDMA-AT for PTSD is on schedule; Australia’s national science agency is exploring medicinal psychedelics; ‘death spiral financings’ arrive to the psychedelics space; and more…
Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium
This week we share our analysis of Phase 2 LSD for Anxiety data shared by MindMed; a look at how at-home ketamine may be next in line for increased DEA/DOJ scrutiny;
our dispatch from PSYCH Symposium ; and more…
Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study Points to Psilocybin for Anorexia
This week: The State of Psychedelic R&D in the UK; COMPASS Study Points to Psilocybin for Anorexia; and more…
Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine Therapy; Psychedelics Research Review
This week: A surpsising big pharma X psychedelics deal; at-home ketamine therapy company scores $23m Series A; March 2022 psychedelics research review; and more…
Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse Stock-Split; Are Magic Mushrooms Giving Investors a Bad Trip?
This week: A surpsising big pharma X psychedelics deal; at-home ketamine therapy company scores $23m Series A; March 2022 psychedelics research review; and more…
Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On
This week: Psychedelic therapy companion app Homecoming has raised $4m in its seed round; Christian Angermayer adds 1m shares to atai stake; we share reader projects; and more…